| abstract |
The invention relates to ligands comprising a portion (for example, a dAb) that has a binding site with binding specificity for an endogenous target compound but does not substantially inhibit the activity of said endogenous target compound. Preferably, the ligand does not bind to the active site of an endogenous target compound. The invention relates to the use of such a ligand for the manufacture of a medicament to increase the half-life, bioavailability, activity or amount of an endogenous target compound to which the ligand binds. |